Clinical Trial Search

Primary: Percentage of Participants With Complete Remission or Complete Remission With Incomplete Recovery Blood Counts — 11 percentage of participants

Primary: Number of Patients With Complete Remission — 3 participants

Primary: Number of Participants According to Health Insurance Type — 265; 44; 253; 27 Participants

Primary: Efficacy of GM-CSF and Pegylated Interferon-alpha 2b When Administered to Patients With AML, ALL, Blast Phase CML, and MDS Relapse After Allogeneic Transplantation…

Primary: the Overall Survival of APL Patients Treated With Retinoic Acid Receptor Alpha (ATRA) and Arsenic Trioxide (ATO) Based Trial — 1; 0; 0; 0 participants — p=<0.05

Primary: Measure Patient Response to High-dose Cytarabine Followed by Clofarabine in Adult Patients With Relapsed or Refractory AML — 17 participants

Primary: The Dose of AC220 That is Safe and Biologically Active When Given in Sequential Combination With Ara-C/Etoposide — 0; 3; 1; 4 Participants

Primary: The Primary End-point is the Number of Patients in CR After Induction Therapy. — 9 Participants

Primary: Complete Remission — 52 percentage of participants

Primary: Percentage of Participants With Complete Remission/Complete Remission With Partial Hematological Recovery (CR/CRh*) During the First Two Treatment Cycles — 35.6…

Primary: Determination of the Maximum Tolerated Dose (MTD) of BI 836858 — NA; NA Milligram (mg)

Primary: Overall Response (CR for ALL Patients), (CR + CRp for AML Patients) — 1; 2; 0; 2 participants

Primary: Phase I Only - Maximum Tolerated Dose (MTD) as Measured by Dose-limiting Toxicities (DLTs) — 1; 0; 0 dose-limiting toxicities

Primary: 3-year Overall Survival Rate of Patients With Relapsed ALL — 94.4; 55.5; 72.63 percentage of participants — p=0.035

Primary: Feasibility of a Novel Combination of Pembrolizumab and Decitabine in Relapsed/Refractory Acute Myeloid Leukemia Participants — 10 Participants

Primary: Achievability of Performing Individualized Drug Screening and Initiating Therapy Based on the Results of the Drug Screen for Poor Risk Patients With Relapsed or…

Primary: Number of Participants With a Response (Complete Remissions (CR), Complete Remissions With Incomplete Platelet Recovery [CRp] and Partial Responses) — 1; 1; 0 participants

Primary: Participants With a Response — 4; 9; 16; 2 participants

Primary: Maximum Tolerated Dose of Clofarabine — 25 mg/m^2 of clofarabine

Primary: Remission Re-induction (CR2) Rate — .646; .660 proportion of participants

Primary: Number of Participants Who Experienced a Dose Limiting Toxicity (DLT) — 0; 0; 12; 2 Participants

Primary: Number of Participants With a Dose-limiting Toxicity — 1 Participants

Primary: Participants With a Complete Response — 34 Participants

Primary: Dose-limiting Toxicity — 0; 0 participants

Primary: Complete Response — 11 percentage of participants

Primary: Overall Survival - Overall and by Calculated Strata (CSR 7-April-11) — 6.6; 6.4; 5.1; 5.5 months — p=0.9951

Primary: Response Rate (CR + CRi + LFS) — 3; 10 participants

Primary: Complete Response Rate — 19 Participants

Primary: Number of Participants With 1 or More Study Drug-Related Adverse Events (AEs) or Any Serious AEs (SAEs) — 6; 5; 6; 0 Participants

Primary: Participants Complete Response — 9 Participants